• 1
    Barrett-Connor E, Criqul MH, Klauber MR, Holdbrook M. Diabetes and hypertension in a community of older adults. Am J Epidemiol. 1981;113:276284.
  • 2
    Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:10531059.
  • 3
    Sowers J, Whaley-Connell A, Hayden M. The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Med. 2011;1:512.
  • 4
    Deedwania P. Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating B-blockers. J Clin Hypertens (Greenwich). 2011;13:5259.
  • 5
    Koya D, King GL. Protein kinase C activation and the development of diabetes complications. Diabetes 1998;47:859866.
  • 6
    Vlassara H, Fuh H, Donnelly T, et al. Advanced glycation end products promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med. 1995;1:447456.
  • 7
    Egan BM, Lu G, Green EL. Vascular effects of non-esterified fatty acids: implications for the cardiovascular risk factor cluster. Prostaglandins Leukot Essent Fatty Acids. 1999;60:411420.
  • 8
    Toft I, Bonaa KH, Ingebresten OC, et al. Fibrinolytic function after dietary supplementation with omega3 polyunsaturated fatty acids. Arterioscler Thromb Vasc Biol. 1997;17:814819.
  • 9
    Cooper SA, Whaley-Connell A, Habibi J, et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol. 2007;293:H2009H2023.
  • 10
    Ren J, Pulakat L, Whaley-Connell A, et al. Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med. 2010;88:9931001.
  • 11
    Sowers JR, Raij L, Jialal I, et al. Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives. J Hypertens. 2010;28:17611769.
  • 12
    Van der Zjil NJ, Moors CC, Goossens GH, et al. Valsartan improves beta-cell function and insulin sensitivity in subjects with impaired glucose metabolism. Diabetes Care. 2011;34:845851.
  • 13
    Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29:25922597.
  • 14
    Poulter NR. Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. J Hyperten Suppl. 2009;27:S3S8.
  • 15
    ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk of vascular events. N Engl J Med. 2008;358:15471559.
  • 16
    Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27:13601369.
  • 17
    The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:15751585.
  • 18
    Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:6168.
  • 19
    Chobanian AV, Bakris GL, Black HR. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and treatment of High Blood Pressure: the JCN 7 report. JAMA. 2003;289:25602571.
  • 20
    European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003; 21:10111054.
  • 21
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension in the Elderly Program. JAMA. 1991;265:32553264.
  • 22
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial. JAMA. 2002;288:29812997.
  • 23
    Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:22172225.
  • 24
    Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. N Engl J Med. 2008;359:24172428.
  • 25
    Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010;56:7785.
  • 26
    Ruggenenti P, Perna A, Ganeva M, et al. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol. 2006;17:34723481.
  • 27
    Haller H, Ito S, Izzo J, et al. Olmesartan for delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907917.
  • 28
    Bilous R, Chatuverdi N, Sjolie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med. 2009;15:1120.
  • 29
    Mauer M, Zinman B, Gardinar R, et al. Renal and retinal effects of enlapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:4051.
  • 30
    Hansson L, Zanchette A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:17551762.
  • 31
    Bakris G. CON: blood pressure treatment goal for patients with diabetes should be <130/80 mm Hg. J Clin Hypertens (Greenwich). 2011;13:263265.
  • 32
    Bakris GL, Sowers JR, on behalf of the American Society of Hypertension Writing Group. ASH Position paper: treatment of hypertension in patients with diabetes–an update. J Am Soc Hyperten. 2010;4:6267.